cept Therapeutics rporated(US:CORT)2025-06-16 17:12Financial Performance and Guidance - Corcept achieved significant revenue growth, increasing from $3 million in 2012 to $482 million in 2024 [13] - The company's 2025 revenue guidance is between $900 million and $950 million [13] - As of March 31, 2025, Corcept had $570.8 million in cash [13] Clinical Trial Results and Drug Development - The GRACE trial showed that 63% of patients with hypertension met the study's response criteria, with a mean improvement of 12.6 mm Hg in SBP and 8.3 mm Hg in DBP [29] - In the GRACE trial, 50% of patients with hyperglycemia met the study's response criteria, showing a mean improvement of 0.7% in HbA1c, 25.2 mg/dL in fasting glucose, and 85.0 mg/dL in 2-hour oGTT [33] - The ROSELLA trial in platinum-resistant ovarian cancer met its primary endpoint, with relacorilant + nab-paclitaxel reducing disease progression risk by 30% (HR=0.70; p=0.008) and mortality risk by 31% (HR=0.69; p=0.01) [62] - In the CATALYST trial, 23.8% of 1,057 patients with difficult-to-control type 2 diabetes were found to have hypercortisolism [21] - Patients who received Korlym in the CATALYST trial experienced a 1.47% reduction in HbA1c compared to a 0.15% reduction in patients who received placebo (p<0.0001) [21] Regulatory and Intellectual Property - Relacorilant's NDA has a PDUFA target date of December 30, 2025 [15, 24] - Corcept holds method of use patents for Korlym extending to 2038 [24] - Corcept holds composition of matter patents for Relacorilant extending to 2038 and method of use, formulation and manufacturing patents extending to 2040 [25]